No proxy on file gives executive pay for Celldex Therapeutics.
No pay on file. Pay comes from the Summary Compensation Table of the proxy statement.
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 9 peers with pay on file was $11.9M. The CEO of Celldex Therapeutics was paid $5.4M, 55% below the median.
- 1Madrigal Pharmaceuticals
- 2BridgeBio Pharma
- 3Protagonist Therapeutics
- 4ImmunityBio
- 5Cytokinetics
- 6Immunovant
- 7Vir Biotechnology
- 8CRISPR Therapeutics AG
- 9Celldex TherapeuticsThis company
- 10Denali Therapeutics
- 11Apellis PharmaceuticalsNot disclosed
- 12ArcellxNot disclosed
- 13ArvinasNot disclosed
- 14BiohavenNot disclosed
- 15Blueprint MedicinesNot disclosed
- 16InhibrxNot disclosed
- 17Iovance BiotherapeuticsNot disclosed
- 18Keros TherapeuticsNot disclosed
- 19Kiniksa PharmaceuticalsNot disclosed
- 20MorphicNot disclosed
- 21Roivant SciencesNot disclosed
- 22SpringWorks TherapeuticsNot disclosed
- 23Syndax PharmaceuticalsNot disclosed
- 24VaxcyteNot disclosed
- 25Zentalis PharmaceuticalsNot disclosed
%20scale(0.100000,-0.100000)'%20fill='%23000000'%20stroke='none'%3e%3cpath%20d='M3195%205489%20c-380%20-49%20-706%20-317%20-831%20-682%20-56%20-163%20-54%20-112%20-54%20-1773%20l0%20-1534%20590%200%20590%200%200%201465%200%201465%20600%200%20600%200%200%20535%200%20535%20-712%20-1%20c-392%20-1%20-744%20-6%20-783%20-10z'/%3e%3c/g%3e%3c/svg%3e)
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.